Agents for treatment of claudin expressing cancer diseases
AssigneesBioNTech SE, Tron Ggmbh, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Ganymed Pharmaceuticals AG
InventorsUgur Sahin, Ozlem Tureci, Christiane Stadler, Julia Holland, Hayat Bahr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
Life of this patent
Estimating the term…
Abstract
The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Claims9
A method of treating a cancer disease comprising administering to a patient a binding agent comprising at least two binding domains, wherein a first binding domain binds to claudin (CLDN) and a second binding domain binds to CD3, wherein the binding agent comprises a variable domain of a heavy chain of an immunoglobulin (VH) with a specificity for a claudin antigen (VH(CLDN)), a variable domain of a light chain of an immunoglobulin (VL) with a specificity for a claudin antigen (VL(CLDN)), a variable domain of a heavy chain of an immunoglobulin (VH) with a specificity for CD3 (VH(CD3)), and a variable domain of a light chain of an immunoglobulin (VL) with a specificity for CD3 (VL(CD3)) wherein said CLDN is CLDN18.2 and said VH(CLDN) comprises an amino acid sequence represented by SEQ ID NO:
- 8 and the VL(CLDN) comprises an amino acid sequence represented by SEQ ID NO:
- 15, wherein said VH(CD3) comprises an amino acid sequence represented by SEQ ID NO:
- 36 and the VL(CD3) comprises an amino acid sequence represented by SEQ ID NO:
- 37, wherein said binding agent comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 38, 39, 40 and 41.
Dependencies are inferred from the claim text.